论文部分内容阅读
目的研究不同抗凝强度华法令对非瓣膜病性心房颤动的预后。方法 100例非瓣膜病性心房颤动患者,随机分为低强度组和中等强度组,各50例。低强度组给予低抗凝强度华法令治疗,中等强度组给予中等抗凝强度华法令治疗。比较两组患者血栓栓塞发生率及出血不良事件发生率。结果中等强度组无血栓栓塞发生,低强度组血栓栓塞发生率为4.00%,低强度组血栓栓塞发生率高于中等强度组,但差异无统计学意义(P>0.05)。中等强度组出血不良事件发生率为8.00%,低强度组出血不良事件发生率为6.00%,中等强度组出血不良事件发生率稍高于低强度组,但差异无统计学意义(P>0.05)。结论不同抗凝强度华法令对非瓣膜病性心房颤动均有良好的治疗效果,可预防血栓栓塞的发生,且出血不良事件发生率较低,相对来说,中等抗凝强度华法令治疗预防血栓栓塞发生效果更好,且不会增加出血不良事件风险。
Objective To investigate the prognosis of non-valvular atrial fibrillation (AF) with different anticoagulant warfarin. Methods One hundred patients with non-valvular atrial fibrillation were randomly divided into low-intensity group and moderate-intensity group, 50 cases each. Low-intensity group was given warfarin with low anticoagulation strength and moderate-intensity group was given warfarin with moderate anticoagulation. The incidence of thromboembolism and the incidence of bleeding-related adverse events in both groups were compared. Results There was no thromboembolism in the medium intensity group. The incidence of thromboembolism in the low intensity group was 4.00%. The incidence of thromboembolism in the low intensity group was higher than that in the middle intensity group (P> 0.05). The incidence of hemorrhagic adverse events in moderate-intensity group was 8.00%, that in low-intensity group was 6.00%, moderate-intensity group was slightly higher than in low-intensity group, but the difference was not statistically significant (P> 0.05) . Conclusions Warfarin with different anticoagulant strength has good curative effect on non-valvular atrial fibrillation and can prevent the occurrence of thromboembolism, and the incidence of bleeding adverse events is relatively low. Relatively speaking, moderate anticoagulation strength warfarin treatment can prevent thrombus Embolization works better and does not increase the risk of bleeding events.